Zimmer Biomet looks to grow ASC market with newest buy
Through the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment to outpace hips and knees, moving forward, according to a Feb. 6 report from Medtech Dive. Zimmer Biomet also expects that the acquisition will give the company a larger presence in the ASC space.
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it ...
Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...
Shares of Zimmer Biomet Holdings Inc. ZBH slipped 5.14% to $102.69 Thursday, on what proved to be an all-around mixed trading ...
In a report released today, Jason Wittes from Roth MKM maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...
Learn more about whether IDEXX Laboratories, Inc. or Zimmer Biomet Holdings, Inc. is a better investment based on AAII's A+ ...
Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...
4h
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and ...
Despite reporting better-than-expected Q4 2024 results, shares of Zimmer Biomet (NYSE:ZBH) fell in the morning hours Thursday after the orthopedic device maker set its 2025 outlook below consensus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback